Panitumumab activity in metastatic colorectal cancer patients with ≥10% epidermal growth factor receptor levels

被引：0
|
作者：
Chan, E.
Neubauer, M.
Swanson, P.
Harker, W.
Burris, H.
Hecht, J.
Navale, L.
Brown, J.
Amado, R.
机构：
[1] Vanderbilt Univ Sch Med, Nashville, TN USA
[2] Kansas City Canc Ctr, Overland Pk, KS USA
[3] Hematol Oncol Associates, Port St Lucie, FL USA
[4] Utah Canc Specialists, Salt Lake City, UT USA
[5] Tennessee Oncol, Nashville, TN USA
[6] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA
[7] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：68 / 68
页数：1
相关论文
共 50 条
  • [21] Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer
    Hutchinson, Ryan A.
    Adams, Richard A.
    Mcart, Darragh G.
    Salto-Tellez, Manuel
    Jasani, Bharat
    Hamilton, Peter W.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2015, 13
  • [22] Abnormal hair growth in patients (pts) with metastatic colorectal cancer (mCRC) treated with the anti-epidermal growth factor receptor (EGFr) monoclonal antibody (mAb) panitumumab (Pmab)
    Tubb, E. E.
    Nugent, M.
    Spielberger, J.
    Axelrod, R. A.
    Mitchell, E. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [23] Does epidermal growth factor receptor status predict activity of cetuximab in colorectal cancer patients?
    Baselga, J
    NATURE CLINICAL PRACTICE ONCOLOGY, 2005, 2 (06): : 284 - 285
  • [24] Does epidermal growth factor receptor status predict activity of cetuximab in colorectal cancer patients?
    Baselga, J
    NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 2005, 2 (07): : C284 - C285
  • [25] Does epidermal growth factor receptor status predict activity of cetuximab in colorectal cancer patients?
    José Baselga
    Nature Clinical Practice Oncology, 2005, 2 (6): : 284 - 285
  • [26] Epidermal growth factor receptor ligands: targets for optimizing treatment of metastatic colorectal cancer
    Foroughi, Siavash
    Tie, Jeanne
    Gibbs, Peter
    Burgess, Antony Wilks
    GROWTH FACTORS, 2019, 37 (5-6) : 209 - 225
  • [27] Anti-Epidermal Growth Factor Receptor Antibodies in the Treatment of Metastatic Colorectal Cancer
    Kendall, Anne
    Lord, Rosemary
    Maisey, Nick
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2010, 5 (02) : 142 - 151
  • [28] Safety of panitumumab, a fully human monoclonal antibody against the epidermal growth factor receptor (EGFr), in patients (pts) with metastatic colorectal cancer (mCRC) across clinical trials
    Peeters, M.
    Van Cutsem, E.
    Berlin, J.
    Hecht, J. R.
    Ruiz, R.
    Navale, L.
    Amado, R.
    Meropol, N. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [29] Association of gene copy number (GCN) of the epidermal growth factor receptor (EGFr) and clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with panitumumab monotherapy
    Berlin, J.
    Hecht, J. R.
    Reiner, M.
    Mullenix, M.
    Suggs, S.
    Radinsky, R.
    Freeman, D.
    Amado, R. G.
    Meropol, N. J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 241 - 241
  • [30] Panitumumab, a monoclonal anti-epidermal growth factor receptor antibody in colorectal cancer: Another one or the one?
    Messersmith, Wells A.
    Hidalgo, Manuel
    CLINICAL CANCER RESEARCH, 2007, 13 (16) : 4664 - 4666
12345